Yr Athro Paul Morgan

Professor

I have worked in the complement system for over thirty years, leading a research group working on basic complement biology and relevance of complement to human disease. I have had a long-standing interest in the membrane attack complex (MAC), its effects on nucleated cells and how nucleated cells respond to MAC attack; this work has led to several seminal discoveries, including the process of nucleated cell recovery from membrane attack and the mechanism by which CD59 regulates MAC formation. More recently, I have demonstrated that the MAC triggers inflammasome activation in diverse cells and contributed to new understanding of MAC structure, using this knowledge to predict function.

Date
Type

2011

Ingram, G., Hakobyan, S., Loveless, S., Robertson, N. and Morgan, B. P. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112(10), pp. 2653-2654. (10.1002/jcb.23204)
Paringe, V., Bloom, A. C., Choy, E. H. S., Morgan, B. P. and Williams, A. S. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
Bloom, A. C., Collins, F., Evans, B. A. J., Aeschlimann, D. P., Morgan, B. P. and Williams, A. S. 2011. CD59 an unexpected protective role in bone [Abstract]. Bone 48, pp. S161-S162.
de Córdoba, S. R., Harris, C. L., Morgan, B. P. and Llorca, O. 2011. Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease 1812(1), pp. 12-22. (10.1016/j.bbadis.2010.09.002)
Morgan, B. P. 2011. Therapeutic Agents for Hereditary Angioedema [Letter]. New England Journal of Medicine 364(1), pp. 86.
Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
Lewis, R. D., Perry, M. J., Guschina, I., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2011. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. American Journal of Pathology 179(4), pp. 1601-1607. (10.1016/j.ajpath.2011.06.015)
Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
Roversi, P. et al. 2011. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proceedings of the National Academy of Sciences of the United States of America 108(31), pp. 12839-12844. (10.1073/pnas.1102167108)
Bubeck, D., Roversi, P., Donev, R. M., Morgan, B. P., Llorca, O. and Lea, S. M. 2011. Structure of human complement C8, a precursor to membrane attack. Journal of Molecular Biology 405(2), pp. 325-330. (10.1016/j.jmb.2010.10.031)
Heurich, B. et al. 2011. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. Journal of Neuroimmunology 235(1-2), pp. 104-109. (10.1016/j.jneuroim.2011.03.011)
Woehrl, B. et al. 2011. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. Journal of Clinical Investigation 121(10), pp. 3943-3953. (10.1172/JCI57522)
Roversi, P. et al. 2011. Structures of the rat complement regulator CrrY. Acta Crystallographica Section F: Structural Biology and Crystallization Communications 67(7), pp. 739-743. (10.1107/S1744309111016551)
Lueck, K. et al. 2011. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye 25(8), pp. 1074-1082. (10.1038/eye.2011.109)

2010

Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133(6), pp. 1602-1611. (10.1093/brain/awq085)
Manickam, B., Jha, P., Hepburn, N. J., Morgan, B. P., Harris, C. L., Bora, P. S. and Bora, N. S. 2010. Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU). Molecular Immunology 48(1-3), pp. 231-239. (10.1016/j.molimm.2010.08.006)
Tediose, T., Kolev, M. V., Baalasubramanian, S., Brennan, P., Morgan, B. P. and Donev, R. M. 2010. Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation [RETRACTED]. Nucleic Acids Research 38(9), pp. 2799-2812. (10.1093/nar/gkq013)
Morgan, B. P. 2010. Hereditary Angioedema - Therapies Old and New [Editorial]. New England Journal of Medicine 363(6), pp. 581-583. (10.1056/NEJMe1006450)
Clark, S. J., Perveen, R., Hakobyan, S., Morgan, B. P., Sim, R. B., Bishop, P. N. and Day, A. J. 2010. Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. Journal of Biological Chemistry 285(39), pp. 30192-30202. (10.1074/jbc.M110.103986)
Bora, N. S. et al. 2010. Recombinant Membrane-targeted Form of CD59 Inhibits the Growth of Choroidal Neovascular Complex in Mice. Journal of Biological Chemistry 285(44), pp. 33826-33833. (10.1074/jbc.M110.153130)
Lewis, R. D., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2010. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Molecular Immunology 47(5), pp. 1098-1105. (10.1016/j.molimm.2009.10.035)
Johnson, S. A. et al. 2010. Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome - A pedigree revisited. Molecular Immunology 47(7-8), pp. 1585-1591. (10.1016/j.molimm.2009.12.001)
Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. Journal of Neuroimmunology 223(1-2), pp. 124-127. (10.1016/j.jneuroim.2010.03.014)
Copland, D. A. et al. 2010. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology 159(3), pp. 303-314. (10.1111/j.1365-2249.2009.04070.x)
Mizuno, T. et al. 2010. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrology Dialysis Transplantation 26(6), pp. 1821-1830. (10.1093/ndt/gfq683)
Harhausen, D., Khojasteh, U., Stahel, P. F., Morgan, B. P., Nietfeld, W., Dirnagl, U. and Trendelenburg, G. 2010. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. Journal of Neuroinflammation 7, pp. 15-26. (10.1186/1742-2094-7-15)
Qiao, F., Atkinson, C., Kindy, M. S., Shunmugavel, A., Morgan, B. P., Song, H. and Tomlinson, S. 2010. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. American Journal of Pathology 177(6), pp. 3061-3070. (10.2353/ajpath.2010.100158)
Ten, V. S. et al. 2010. Complement component C1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. Journal of Neuroscience 30(6), pp. 2077-2087. (10.1523/JNEUROSCI.5249-09.2010)
Hakobyan, S., Tortajada, A., Harris, C. L., de Córdoba, S. R. and Morgan, B. P. 2010. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney International 78(8), pp. 782-788. (10.1038/ki.2010.275)

2009

Ramaglia, V. et al. 2009. Complement inhibition accelerates regeneration in a model of peripheral nerve injury. Molecular Immunology 47(2-3), pp. 302-309. (10.1016/j.molimm.2009.09.019)
Tortajada, A., Montes, T., Martinez-Barricarte, R., Morgan, B. P., Harris, C. L. and de Cordoba, S. R. 2009. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Human Molecular Genetics 18(18), pp. 3452-3461. (10.1093/hmg/ddp289)
Ramaglia, V., King, R. H. M., Morgan, B. P. and Baas, F. 2009. Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Molecular Immunology 46(8-9), pp. 1892-1896. (10.1016/j.molimm.2009.01.017)
Hughes, T. R., Ross, K. S., Cowan, G. J. M., Baalasubramanian, S., Harris, C. L., Mitchell, T. J. and Morgan, B. P. 2009. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Molecular Immunology 46(7), pp. 1561-1567. (10.1016/j.molimm.2009.01.003)
Montes, T., Tortajada, A., Morgan, B. P., Rodriguez de Cordoba, S. and Harris, C. L. 2009. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proceedings of the National Academy of Sciences 106(11), pp. 4366-4371. (10.1073/pnas.0812584106)
Scola, A., Johswich, K., Morgan, B. P., Klos, A. and Monk, P. N. 2009. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Molecular Immunology 46(6), pp. 1149-1162. (10.1016/j.molimm.2008.11.001)
Ruseva, M. M. et al. 2009. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology 46(5), pp. 803-811. (10.1016/j.molimm.2008.09.003)
Kolev, M., Ruseva, M. M., Harris, C. L., Morgan, B. P. and Donev, R. M. 2009. Implication of complement system and its regulators in Alzheimer's Disease. Current Neuropharmacology 7(1), pp. 1-8.
Baalasubramanian, S., Longhi, M. P., Gallagher, K. M. E., Betts, G. J., Morgan, B. P., Godkin, A. J. and Gallimore, A. M. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182(9), pp. 5203-5207. (10.4049/jimmunol.0804243)
Arnold, D. F., Roberts, A. G., Thomas, A. G., Ferry, B., Morgan, B. P. and Chapel, H. 2009. A novel mutation in a patient with a deficiency of the eighth component of complement associated with recurrent meningococcal meningitis. Journal of Clinical Immunology 29(5), pp. 691-695. (10.1007/s10875-009-9295-7)
Kolev, M., Tediose, T., Baalasubramanian, S., Harris, C. L., Thome, J., Morgan, B. P. and Donev, R. M. 2009. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. The Pharmacogenomics Journal 10(1), pp. 12-19. (10.1038/tpj.2009.52)
Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology 155(2), pp. 128-139. (10.1111/j.1365-2249.2008.03830.x)
Stahel, P. F. et al. 2009. Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. Journal of Neuroinflammation 6, pp. 2-13. (10.1186/1742-2094-6-2)
Savage, D. B. et al. 2009. Complement Abnormalities in Acquired Lipodystrophy Revisited. Journal of Clinical Endocrinology & Metabolism 94(1), pp. 10-16. (10.1210/jc.2008-1703)
McColl, A., Bournazos, S., Franz, S., Perretti, M., Morgan, B. P., Haslett, C. and Dransfield, I. 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. The Journal of Immunology 183(3), pp. 2167-2175. (10.4049/jimmunol.0803503)
Mizuno, M. et al. 2009. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. The Journal of Immunology 183(2), pp. 1403-1412. (10.4049/jimmunol.0804245)

2008

Hakobyan, S. et al. 2008. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. Journal of Biological Chemistry 283(45), pp. 30451-30460. (10.1074/jbc.M803648200)
Donev, R. M., Gray, L. C., Baalasubramanian, S., Hughes, T. R., Van Den Berg, C. W. and Morgan, B. P. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma [RETRACTED]. Cancer Research 68(14), pp. 5979-5987. (10.1158/0008-5472.CAN-07-6828)
Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
Ramaglia, V. et al. 2008. Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. American Journal of Pathology 172(4), pp. 1043-1052. (10.2353/ajpath.2008.070660)
Hepburn, N. J., Ruseva, M. M., Harris, C. L. and Morgan, B. P. 2008. Complement, roles in renal disease and modulation for therapy. Clinical Nephrology 70(5), pp. 357-376.
Donev, R. M., Baalasubramanian, S., Mizuno, M. and Morgan, B. P. 2008. The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility [RETRACTED]. Molecular Immunology 45(2), pp. 534-542. (10.1016/j.molimm.2007.05.011)
Hepburn, N. J., Chamberlain-Banoub, J. L., Williams, A. S., Morgan, B. P. and Harris, C. L. 2008. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Molecular Immunology 45(2), pp. 395-405. (10.1016/j.molimm.2007.06.144)
Willison, H. J., Halstead, S. K., Beveridge, E., Zitman, F. M. P., Greenshields, K. N., Morgan, B. P. and Plomp, J. J. 2008. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. Journal of Neuroimmunology 201, pp. 172-182. (10.1016/j.jneuroim.2008.05.028)
Leite, M. I. et al. 2008. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131(7), pp. 1940-1952. (10.1093/brain/awn092)
Hakobyan, S. et al. 2008. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Investigative Ophthalmology and Visual Science 49(5), pp. 1983-1990. (10.1167/iovs.07-1523)

2007

Athisayaraj, T., Henley, P., Asderakis, A., Morgan, B. and Chavez, R. 2007. Complement activation associated to ischaemia and reperfusion in clinical renal transplantation. Molecular Immunology 44(16), pp. 3935. (10.1016/j.molimm.2007.06.065)
Hepburn, N. J., Williams, A. S., Morgan, B. P. and Harris, C. L. 2007. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282, pp. 8292-8299. (10.1074/jbc.M609858200)
Harris, C. L., Cordoba, S. R. d., Jorge, E. G. d. and Morgan, B. P. 2007. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proceedings of the National Academy of Sciences 104(1), pp. 240-5. (10.1073/pnas.0603420103)
Harris, C. L., Morgan, B. P., Pettigrew, D. and Lea, S. 2007. Decay-accelerating factor must bind both components of the complement alternative pathway c3 convertase to mediate efficient decay. Journal of Immunology 178, pp. 352-359.
Hepburn, N. J., Williams, A. S., Chamberlain, J. C., Hamer, J., Nunn, M. A., Morgan, B. P. and Harris, C. L. 2007. In vivo characterisation and therapeutic efficacy of a C5-specific inhibitor [Abstract]. Molecular Immunology 44(1-3), pp. 183-183. (10.1016/j.molimm.2006.07.087)
Mizuno, M., Donev, R. M., Harris, C. L. and Morgan, B. P. 2007. CD55 in rat male reproductive tissue: Differential expression in testis and expression of a unique truncated isoform on spermatozoa. Molecular Immunology 44(7), pp. 1613-1622. (10.1016/j.molimm.2006.08.018)
Sivasankar, B. et al. 2007. CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Molecular Immunology 44(11), pp. 2978-2987. (10.1016/j.molimm.2006.12.025)

2006

Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176(5), pp. 2915-2923.
Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. The Journal of Immunology 176(5), pp. 2915-2923. (10.4049/jimmunol.176.5.2915)
Donev, R. M., Cole, D. S., Sivanaskar, B., Hughes, T. R. and Morgan, B. P. 2006. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59 [RETRACTED]. Cancer Research 66(4), pp. 2451-8. (10.1158/0008-5472.CAN-05-3191)
Donev, R. M. and Morgan, B. P. 2006. A quantitative method for comparison of expression of alternatively spliced genes using different primer pairs. Journal of Biochemical and Biophysical Methods 66(1-3), pp. 23-31. (10.1016/j.jbbm.2005.11.001)

2005

Longhi, M. P., Baalasubramanian, S., Omidvar, N., Morgan, B. P. and Gallimore, A. M. 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175(11), pp. 7098-7102.
Harris, C. L., Morgan, B. P., Lea, S. M. and Abbott, R. J. 2005. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). Journal of Biological Chemistry 280(4), pp. 2569-78. (10.1074/jbc.M410179200)
Van Beek, J. and Morgan, B. P. 2005. The role of complement in EAE. In: Lavi, E. and Constantinescu, C. S. eds. Experimental Models of Multple Sclerosis. Dordrecht: Kluwer Academic, pp. 245-267., (10.1007/0-387-25518-4_12)

2004

Morgan, B. P., Griffiths, M., Khanom, H., Taylor, S. M. and Neal, J. W. 2004. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clinical & Experimental Immunology 138(3), pp. 430-8. (10.1111/j.1365-2249.2004.02646.x)
Baalasubramanian, S., Harris, C. L., Donev, R. M., Mizuno, M., Omidvar, N., Song, W. and Morgan, B. P. 2004. CD59a is the primary regulator of membrane attack complex assembly in the mouse. Journal of Immunology 173, pp. 3684-3692.
Williams, A. S., Mizuno, M., Richards, P. J., Holt, D. S. and Morgan, B. P. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis & Rheumatism 50(9), pp. 3035-3044. (10.1002/art.20478)
Rushmere, N. K., Knowlden, J. M., Gee, J. M. W., Harper, M. E., Robertson, J. F. R., Morgan, B. P. and Nicholson, R. I. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108(6), pp. 930-936. (10.1002/ijc.11606)
Mead, R. J., Neal, J. W., Griffiths, M. R., Linington, C., Botto, M., Lassmann, H. and Morgan, B. P. 2004. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Laboratory Investigation 84, pp. 21-28. (10.1038/labinvest.3700015)
Harris, C. L. and Morgan, B. 2004. The many faces of the membrane regulators of complement. In: Szebeni, J. ed. The Complement System: Novel Roles in Health and Disease. Boston: Kluwer, pp. 129-166.
Sivasankar, B., Mizuno, M., Donev, R. M., Omidvar, N., Harris, C. L., Song, W. C. and Morgan, B. P. 2004. CD59b is expressed at low level on mouse erythrocytes and has a negligible protective role in the presence of CD59a. Molecular Immunology 41(2-3), pp. 307-308. (10.1016/j.molimm.2004.03.002)

2003

Harris, C. L., Hughes, C. E., Williams, A. S., Goodfellow, I., Evans, D. J., Caterson, B. and Morgan, B. P. 2003. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. The Journal of Biological Chemistry 278(38), pp. 36068-36076. (10.1074/jbc.M306351200)
Clayton, A., Harris, C. L., Morgan, B. P. and Mason, M. D. 2003. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. European Journal of Immunology 33(2), pp. 522-31. (10.1002/immu.200310028)
Spiller, O. B., Robinson, M., O'Donnell, E., Milligan, S., Morgan, B. P., Davison, A. J. and Blackbourn, D. J. 2003. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. Journal of Virology 77(1), pp. 592-599. (10.1128/JVI.77.1.592-599.2003)

2002

McGreal, E. P., Ikawaki, N., Akatsu, H., Morgan, B. P. and Gasque, P. 2002. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. Journal of Immunology 168, pp. 5222-5232.
Hiscox, S. E., Hallett, M. B., Morgan, B. P. and Van Den Berg, C. W. 2002. GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications 293(2), pp. 714-721. (10.1016/S0006-291X(02)00280-2)
Okosieme, O. E., Parkes, A. B., McCullough, B., Doukidis, D., Morgan, B. P., Richards, C. J. and Lazarus, J. H. 2002. Complement activation in postpartum thyroiditis. QJM: An International Journal of Medicine 95(3), pp. 173-179. (10.1093/qjmed/95.3.173)
Mead, R. J., Singhrao, S. K., Neal, J. W., Lassmann, H. and Morgan, B. P. 2002. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. Journal of Immunology 168, pp. 458-465.

2001

Holt, D. S., Botto, M., Bygrave, A. E., Hanna, S. M., Walport, M. J. and Morgan, B. P. 2001. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98(2), pp. 442-9. (10.1182/blood.V98.2.442)

2000

Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J. and Morgan, B. P. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49(1-2), pp. 171-186. (10.1016/S0162-3109(00)80302-1)
Labeta, M. et al. 2000. Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. Journal of Experimental Medicine 191, pp. 1807-1812. (10.1084/jem.191.10.1807)
Orren, A. 2000. Screening for complement deficiency. In: Morgan, B. P. ed. Complement Methods and Protocols., Vol. 150. Methods in Molecular Biology Springer, pp. 139-158., (10.1385/1-59259-056-X:139)

1996

Jones, J., Davies, E., Morgan, B. P. and Hallett, M. B. 1996. Effect of inhibitors of tyrosine kinase and phospholipase C on neutrophil response to perforin attack. Immunology 89(Supp1), pp. R187-R187.

1995

Van Den Berg, C. W., Cinek, T., Hallett, M. B., Horejsi, V. and Morgan, B. P. 1995. Exogenous CD59 incorporated into U937 cells through its glycosyl phosphatidylinositol anchor becomes associated with signalling molecules in a time dependent manner. Biochemical Society Transactions 23(2), pp. 269S. (10.1042/bst023269s)

1994

Taylor, K. M., Morgan, B. P. and Campbell, A. K. 1994. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity. Immunology 83(3), pp. 501-506.

My research throughout my career has related to the complement system, its regulation and roles in disease. My current research focusses on roles of complement and other inflammatory pathways in disease with a particular focus on neurological disease.

Current and Recent Grants:

Dementia Research Institute Cardiff (MRC-funded) Programme: 2017-2022. Value £1.5M. Complement in Alzheimer’s disease: from gene discovery to mechanisms and better drugs.
Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease. 2015-2020. Value £5.7M (app. £0.4M to Cardiff). Lead for inflammatory biomarkers theme.
Alzheimer’s Research UK Pilot Grant. 2015-2016. Value £49,437. “Complement
and microglial activation in mouse models of dementia”.
BBSRC Case Studentship with GSK; 2015-2019. Value app. £180,000. “Inflammatory effects of the complement terminal pathway: exploring the molecular mechanisms”.
MS Society Studentship; 2012-2015; Value £104,350. Title: “Mechanisms and roles of microglial priming and activation in experimental demyelination and human MS”.
BBSRC CASE Studentship with GSK; 2012-2016; Value: ~£150,000.Title: “Mechanisms responsible for differential bactericidal activities of human and rabbit complement against Neisseria meningitidis”.
Fight for Sight Project Grant; 2013-2016; Value: £169,937. Title: 'The complotype as a predictor of disease and response to therapy in AMD'.
BHF Project Grant; 2013-2016; Value; £297,000. Title: “The role of complement dysregulation and C3adesArg in atherosclerosis".
Sponsor of 17 Research Fellows (MRC; WT; ARC); Supervised >30 PhD/ MD students.

Over thirty years experience of delivering lectures and tutorials on various aspects of Biochemistry and Immunology to Medical Students and Science Students.

As Dean of Medicine (2008-2013), led the introduction of a completely new integrated spiral curriculum across all five years of the MBBCh course.

Small group teaching lead and OSCE examiner for medical students.

Supervised over thirty students to successful completion of PhD, MD or MSc degrees.

Lead for the GW4CAT Clinical Academic Training Programme.

Current position:

Professor of Immunology, Director of Systems Immunity URI, Cardiff University

Previous positions:

1980-1981: House Physician, Cardiff Hospital Group.

1981-1984: MRC Training Fellow, Medical Biochemistry, Welsh National School of Medicine.

1984-1985: MRC Travelling Fellow, Johns Hopkins Medical School, Baltimore, and University of Florida, Gainesville, Florida

1/1/86-30/9/87: Clinical Lecturer in Medical Biochemistry, University of Wales College of Medicine.

1/10/87 – 30/9/01: Wellcome Trust Senior Clinical Research Fellow and Honorary Consultant, Medical Biochemistry, Wales College of Medicine. Appointed Professor from 1/11/95.

1/10/01 – 31/3/09: Head, Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University. Honorary Consultant in Medical Biochemistry; Cardiff and Vale NHS Trust.

1/09/07 – 31/3/09: Dean of Medical Research, School of Medicine, Cardiff University.

1/04/09 – 31/12/13: Dean of Medicine and Head of School, School of Medicine, Cardiff University.

Education:

1977 B.Sc. (1st Class Hons) Medical Biochemistry.

1980 M.B., B.Ch. (University of Wales).

1984 Ph.D. (Wales) "Biochemistry and Pathology of Complement Component C9".

1988 Membership of the Royal College of Pathologists (MRCPath).

1997 Fellowship of the Royal College of Pathologists (FRCPath).

Anrhydeddau a dyfarniadau

Awards and elections:

1999 Elected to Fellowship of the Academy of Medical Sciences (FMedSci)

2000 Elected to Membership of the Royal College of Physicians (MRCP).

2001 Elected to Membership of the Association of Physicians.

2002-2007 Chair; European Complement Network

2011-2014 President; International Complement Society

2015 Elected to Fellowship of Academia Europaea.

National/International funding roles and panels:

1994-2000 Member, International Interest Group of The Wellcome Trust.

2001 – 2006 Member, MRC Clinical Training and Career Development Panel.

2004 - 2006 Member, Wellcome Trust Basic Immunology and Infection Panel.

2005-2008 Council Member, Academy of Medical Sciences.

2006-2012 Member then Chair, Wellcome Trust Clinical Fellowship Interview Panel.

2008- 2012 Member, Wellcome Trust Pathogens, Immunology & Population Health Strategy Committee

2013- 2017 Member, Biology and Medicine Panel, Research Grants Council of Hong Kong.

2011-2015 Council Member, Medical Research Council

Aelodaethau proffesiynol

Fellow of the Academy of Medical Sciences (FMedSci)

Fellow of the Royal College of Pathologists

Member of the Royal College of Physicians (MRCP).

Member of the Association of Physicians.

Fellow of the Academia Europaea.

Safleoedd academaidd blaenorol

01/2014- present: Professor of Immunology, Director of Systems Immunity URI, Cardiff University.
04/09 – 12/13: Dean of Medicine and Head of School, School of Medicine, Cardiff University.
09/07 – 03/09: Dean of Medical Research, School of Medicine, Cardiff University.
10/01 – 03/09: Head, Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University. Honorary Consultant in Medical Biochemistry; Cardiff and Vale NHS Trust.
10/87 – 09/01: Wellcome Trust Senior Clinical Research Fellow and Honorary Consultant, Medical Biochemistry, Wales College of Medicine. Appointed Professor from 1/11/95.

Pwyllgorau ac adolygu

Grants committees and panels:

Medical Research Council; Council Member (2011- 2015).

Chair, NISCHR Grants Funding committee; (2013- current).

Chair, Wellcome Trust Clinical Fellowship Interview Panel from December 2007-2012.

Member, Wellcome Trust Clinical Fellowship Interview Panel (2006 - 2012);

Member, Wellcome Trust Pathogens, Immunology & Population Health Strategy Committee (2008- 2012).

Member, MRC College of Experts (2005 - 2010).

Deputy Chair, Wales Office of Research and Development Funding Committee, (2004 - 2009);

Member, Wellcome Trust Basic Immunology and Infection Panel (2004 - 2006).

Member, MRC Clinical Training and Career Development Panel (2001 - 2006).

Member, International Interest Group of The Wellcome Trust (responsible for all overseas funding initiatives by The Trust) (1994-2000).

National/International bodies:

Council Member; Academy of Medical Sciences (2005-2008).

Member; UCEA Clinical Academic Staff Advisory Group (CASAG) (2009-2015).

Member; UK Healthcare Education Advisory Committee (UK HEAC) (2010-2015).

Member; Welsh Medical Committee (2009 – 2013).

Member; AcMedSci committee advising on MB PhD schemes.

Member; AcMedSci Academic Careers Committee.

Member; RAE 2008 sub-panel A3 (Infection and Immunity).

Member; NISCHR Senior Faculty (2013- ongoing).

Former Meetings Secretary, Treasurer, Trustee and Member of Council, British Society for Immunology.

UK Representative on International Complement Society Committee (2003- 2015).

Chair of European Complement Network (2001-2007).

Deputy Chair, Grants Review Committee, Wales Office of Research and Development (WORD).

Member of Scientific Strategy Committee, Tenovus Cancer Research (2000 - 2012).

Member, Biology and Medicine Panel, Research Grant Council of Hong Kong (2013-ongoing).

Contact Details

MorganBP@caerdydd.ac.uk
+44 29206 87096
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell 3F08, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN

Targedu llid er mwyn mynd i’r afael â COVID hir

Yr Athro Paul Morgan

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012